Tune Therapeutics raises $175M Series B for epigenetic editing
In genetic medicine, a drumbeat of layoffs and pipeline cuts has replaced the excitement of just a few years ago, when fresh financing rounds were coming almost as often as new editing technologies and...
View ArticleThe embryo editing debate is back, revived by Nature article
Six years ago, Chinese researcher He Jiankui stunned the world by announcing the birth of the first two babies whose genes were edited as embryos. An ethical red line was crossed and condemnation from...
View ArticleJ&J looks at potential bid for Intra-Cellular — report
Johnson & Johnson is considering an acquisition of CNS drugmaker Intra-Cellular Therapies, according to anonymous sources cited in a Bloomberg News report on Sunday. If J&J follows through with...
View ArticleLantheus to buy Life Molecular Imaging for $350M, netting Alzheimer's diagnostic
Radiopharmaceutical maker Lantheus Holdings plans to acquire Life Molecular Imaging for $350 million in a bid to build up its commercial Alzheimer’s diagnostics business. In addition to the $350...
View ArticleGSK acquires IDRx and its rare cancer drug for $1B upfront
Is the frenzy of JPM dealmaking finally underway? GSK announced Monday morning that it will acquire the privately-held biotech IDRx for $1 billion upfront, bringing a rare cancer treatment into the...
View ArticleBayer’s BlueRock now plans to bring Parkinson’s cell therapy straight to...
Bayer's experimental Parkinson’s disease therapy made from stem cells will soon enter late-stage studies, marking a key test for regenerative medicine in neurologic conditions. The therapy, known as...
View ArticleRegor’s obesity pill posts muted weight loss in Phase 2a, enters new trial
The weight loss with Regor Therapeutics’ obesity pill does not look quite as strong as competing products — and the biotech’s interest in finding a partner for the asset might be harder to gratify....
View ArticleGilead taps into STAT6 space via $250M deal with Leo Pharma
Gilead has inked a deal to license Leo Pharma’s portfolio of oral STAT6 candidates for inflammatory diseases, less than a month after Johnson & Johnson dipped its toes into the same arena. Gilead...
View Article#JPM25: Day 1 at the JP Morgan Healthcare Conference
It’s day 1 at JP Morgan Healthcare Conference, and the dealmaking is already underway with three early announcements: GSK will acquire the privately-held biotech IDRx for $1 billion upfront; Lilly is...
View ArticleUpdated: J&J to buy Intra-Cellular for $14.6B in latest neuroscience bet
Johnson & Johnson is acquiring Intra-Cellular Therapies for $14.6 billion in the biggest biotech M&A transaction since 2023. The deal signals growing excitement in neuroscience after several...
View ArticleAstraZeneca, CRISPR tools supplier Synthego ink gene editing enzyme licensing...
Genome engineering business Synthego will have access to AstraZeneca’s CRISPR gene editing enzyme in its second licensing agreement in the past year. Synthego plans on combining the enzyme, branded as...
View ArticleLilly to acquire cancer biotech Scorpion, which shares a co-founder with Loxo
Eli Lilly, the most talked-about pharmaceutical company in recent years, is buying cancer startup Scorpion Therapeutics about half a year after its $150 million Series C. The deal is worth a total ...
View ArticleAragen gets $100M to expand manufacturing footprint
Indian CDMO Aragen Life Sciences has secured a $100 million investment from Singapore-headquartered private equity firm Quadria Capital. Aragen will use the investment to expand its facilities to meet...
View ArticleNormunity nabs $75M Series B to advance T cell engager and launch first trial
A startup from PD-L1 pioneer Lieping Chen has closed a new financing round. Normunity raised $75 million in a Series B, the company announced Monday, which it hopes to use to ...
View ArticleHengrui and Kailera’s injected incretin posts best-in-class obesity data in...
At 22.8% at 36 weeks, the weight loss seen with Chinese drugmaker Jiangsu Hengrui Pharmaceuticals’ injected GLP-1/GIP dual agonist in its Phase 2 trial looks potentially best-in-class. The candidate...
View ArticleImmunovant’s $450M private placement; Biomea becomes an obesity biotech
Plus, news about Ashvattha, Bausch + Lomb, Whitecap Biosciences, Labviva, Scribe, Sanofi, X4, Apellis and Aileron Therapeutics: Immunovant nets $450M private placement: The proceeds will help afford a...
View ArticleAbbVie partners with Simcere Pharma unit to develop myeloma drug
AbbVie is teaming up with Simcere Zaiming to develop an investigational new drug candidate for multiple myeloma. The agreement, announced Monday, reflects a trend of licensing
View ArticleFederal Circuit upholds Novartis patent for heart drug Entresto
The US Court of Appeals for the Federal Circuit on Friday found a key patent of Novartis' Entresto valid, reversing a lower court ruling and potentially putting up a short-lived roadblock to generic...
View ArticleModerna lowers 2025 revenue estimate, announces more cost cuts
Moderna is slashing its 2025 revenue estimate by $1 billion and expanding cost-cutting measures as it continues to struggle with a slow RSV launch and a shaky Covid-19 vaccine market. Executives are
View Article